Vertex Makes A $10 Billion Deal; Biotech Stock Doubles

The article discusses Crinetics Pharmaceuticals, whose stock surged nearly 99% after Vertex Pharmaceuticals announced a $10 billion acquisition of the company. Crinetics specializes in drugs for endocrinology-related diseases, particularly Palsonify, which treats acromegaly and holds potential for significant peak sales. The merger is seen as a strategic fit for Vertex as it diversifies its portfolio and strengthens its position in biotechnology. The article highlights the drug's promise in treating congenital adrenal hyperplasia and addresses the broader market sentiment favoring healthcare stocks.

Store

SubscribeSign In

My Subscriptions

Customer Center My Stock Lists Email Preferences Help & Support Sign Out

SubscribeSign In

Search stocks or keywords

Sections

My IBD

Market Trend

MARKET TREND

The Big Picture Stock Market Today ETF Market Strategy Stock Market Data Psychological Indicators New? Start Here IBD Digital: 2 Months for $20

Stock Lists

STOCK LISTS

IBD 50 IBD Sector Leaders IBD Big Cap 20 IBD Long-Term Leaders IPO Leaders My Stock Lists Stock Lists Update Stocks On The Move New Highs Stock Spotlight Stocks Near Buy Zone RS Line At New High Rising Profit Estimates Stocks Funds Are Buying Your Weekly Review Breakout Stocks Index IBD ETF Indexes IBD Data Tables IBD Digital: 2 Months for $20 New? Start Here

Research

STOCK RESEARCH

IBD Stock Checkup Stock Of The Day Screen Of The Day IBD Charts Stock Screener Swing Trading Options Investing Action Plan Earnings Preview Earnings Calendar IBD Industry Themes The New America Best ETFs Best Mutual Funds The Income Investor IBD Stock Analysis Industry Snapshot IBD 50 Stocks To Watch IBD Data Stories IBD Digital: 2 Months for $20

News

NEWS

eIBD Technology Magnificent Seven Stocks Personal Finance Special Reports Cryptocurrency Retirement Management

ECONOMY

Economic Calendar Economic News IBD Digital: 2 Months for $20

Videos

VIDEOS & PODCASTS

IBD Live How To Invest Videos Options Videos Investing With IBD Podcast Growth Stories Podcast Webinars Online Courses IBD Digital: 2 Months for $20

Learn

HOW TO INVEST

How To Invest In Stocks Stock Investing Keys Stock Market Timing Track Market Trends How To Read Stock Charts How To Buy Stocks When To Sell Stocks Short Selling Swing Trading What Is Crypto

EDUCATIONAL RESOURCES

New to IBD Investor's Corner Investing With IBD Podcast Events & Webinars IBD Moneyworks 12 Days Of Learning Investing Infographics Premium Online Courses Premium Workshops

Store

My Products

Founder's Club SwingTrader Leaderboard MarketSurge eIBD IBD Digital IBD Live

Recently Searched

EWP0.35%

News 1:52 PM ET

This European Stock Market Quietly Becomes A Regional Leader To Watch

XOM2.45%

Options 1:39 PM ET

ExxonMobil Trade Can Pump Out A Premium Or Discounted Shares For The Oil Heavyweight

LMT0.98%

News 1:30 PM ET

NATO Summit Centers On F-35 Sales, Defense Deals, Spending. Lockheed Boosts Production.

Crinetics stock nearly doubled early Tuesday after Vertex Pharmaceuticals pledged $10 billion to buy the endocrinology-focused biotech company.

The smaller company sells Palsonify, a treatment for acromegaly, and is working on a treatment for congenital adrenal hyperplasia, or CAH, called atumelnant. The Crinetics Pharmaceuticals' ( CRNX) drugs are daily pills and would add an estimated $5 billion in peak sales to Vertex Pharmaceuticals' ( VRTX) top line, the companies said in a news release.

↑X

Investors Are Rotating Into Healthcare. Here’s Why.

Janus Henderson portfolio manager Dan Lyons discusses why he sees opportunities for market outperformance in the healthcare sector as innovations in biotechnology, pharmaceuticals and medical devices proliferate.

Endocrinology Pipeline

Palsonify gained Food and Drug Administration approval in September to treat acromegaly, a slow-progressing disease that causes excess growth hormone in adulthood. This leads to enlargement of the face, jaw, hands and feet. In most cases, it's caused by a noncancerous tumor on the pituitary gland. The company estimates there are about 20,000 diagnosed patients in the U.S. with acromegaly.

Crinetics' drug works by lowering insulin-like growth factor to alleviate symptoms, including joint pain, headaches and nausea.

The company is also testing out a daily pill to treat CAH, a group of inherited disorders that affect the adrenal glands. This leads to the overproduction of male sex hormones known as androgens. Typically, patients treated their CAH with high steroids known as glucocorticoids. But those carry a host of side effects.

Neurocrine Biosciences ( NBIX) won approval for its drug Crenessity. Crinetics is hoping to follow suit.

"Vertex sees a multibillion dollar opportunity in CAH alone for the product," William Blair's Minter said. "This includes global markets, but it is the first time we have heard of a multibillion sales potential for a CAH product. It is also bullish for Neurocrine's Crenessity, in our view, currently annualizing $613.2 million after (about) 18 months of launch."

Crinetics notes that atumelnant has also shown promise in Cushing's syndrome, a rare hormonal disorder in which too much cortisol exists in the body. This causes rapid weight gain, a hump between the shoulders, bruising, muscle weakness and high blood pressure, among other symptoms.

IBD Newsletters

Get exclusive IBD analysis and actionable news daily.

'Strategic Fit For Vertex'

Vertex Chief Executive Reshma Kewalramani called Crinetics "an excellent strategic fit for Vertex."

"Its focus on serious diseases in specialty markets with significant unmet need, well-understood causal human biology, and potentially best-in-class medicines ... could deliver transformative benefit to patients," she said in a statement.

Oppenheimer analyst Leland Gershell says there aren't any major obstacles to the deal closing as expected this quarter. The endocrine focus diversifies Vertex's dominance in cystic fibrosis beyond its hematology, kidney and type 1 diabetes verticals.

Kewalramani, Vertex's CEO, says the company will build on its expertise in rare genetic diseases to continue building up Palsonify. Vertex partners with Crispr Therapeutics ( CRSP) on its gene-editing approach to two blood diseases.

Crinetics stock has spent all of 2026 consolidating with a buy point at 57.99, MarketSurge shows. Shares broke out Tuesday morning. The relative strength line also hit a new high.

Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.

YOU MAY ALSO LIKE:

Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development

Bayer Surges After Winning Its Supreme Court Roundup Challenge

Looking For The Next Big Stock Market Winners? Start With These 3 Steps

Options Trading: How To Start Using Options, How To Manage Risk

Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader